Frauke Bentzien

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

Fawn Qian, Stefan Engst, Peiwen Yu et al. · Cancer Research · 2009 · 338 citations

Medicine, Oncology, Pharmacology +17

Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: An efficient mechanism for the regulation of angiogenesis

Ingrid Struman, Frauke Bentzien, Hsinyu Lee et al. · Proceedings of the National Academy of Sciences · 1999 · 278 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +16

Induction of an angiogenic phenotype in endometriotic stromal cell cultures by interleukin-1 

Dan I. Lebovic, Frauke Bentzien, Victor A. Chao et al. · Molecular Human Reproduction · 2000 · 189 citations · Full text

Medicine, Gynecology, Immunology +12

<i>In Vitro</i> and <i>In Vivo</i> Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Frauke Bentzien, Marcus Zuzow, Nathan Heald et al. · Thyroid · 2013 · 130 citations · Full text

Medicine, Oncology, Pharmacology +16